We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sanofi is not bowing out of its efforts to buy Medivation, warning the company’s board that if it continues to brush off its overtures, it will pursue a hostile bid. Read More
The UK’s National Institute for Health and Care Excellence is recommending reimbursement of Novartis’ drug combination Mekinist and Tafinlar for treating unresectable or metastatic melanoma in patients with BRAF V600 mutations. Read More